Last reviewed · How we verify
Hetrombopag Olamine+Standard Therapy
Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts.
Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts. Used for Immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C.
At a glance
| Generic name | Hetrombopag Olamine+Standard Therapy |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (c-Mpl) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Hetrombopag binds to and activates the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells, promoting their proliferation and differentiation into mature megakaryocytes, which subsequently release platelets into the bloodstream. This mechanism increases circulating platelet counts in patients with thrombocytopenia. When combined with standard therapy, it may enhance treatment efficacy in conditions where low platelet counts limit therapeutic options.
Approved indications
- Immune thrombocytopenia (ITP)
- Thrombocytopenia in patients with chronic hepatitis C
Common side effects
- Headache
- Fatigue
- Nausea
- Thrombotic events
- Bone marrow fibrosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: